CIK 0000897448
- Accelerated filer
AMARIN CORP PLCUK
Sign in to watch- Ticker
- AMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- Operating
- Phone
- +353 16699020
- Business address
- SPACES SOUTH DOCKLANDS, BLOCK C, 77 SIR JOHN ROGERSON'S QUAY, DUBLIN 2, Ireland
- Former names
- AMARIN CORP PLC\UK, AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-03-04 | Ekman Lars Director | Option exercise | +6,390 | $1.87 | $12K | 25,974 |
| 2019-03-04 | Ekman Lars Director | Option exercise | +28,500 | $1.87 | $53K | 54,474 |
| 2019-03-04 | Ekman Lars Director | Option exercise | +35,258 | $2.19 | $77K | 89,732 |
| 2019-03-04 | Ekman Lars Director | Option exercise | +17,358 | $2.50 | $43K | 107,090 |
| 2019-03-04 | Ekman Lars Director | Option exercise | +28,287 | $2.50 | $71K | 135,377 |
| 2019-03-04 | Ekman Lars Director | Sale | −98,677 | $21.16 | $2.1M | 36,700 |
| 2019-03-04 | Ekman Lars Director | Sale | −36,700 | $21.71 | $797K | 0 |
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −19,584 | 0 | ||
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −6,390 | 0 | ||
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −28,500 | 0 | ||
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −35,258 | 0 | ||
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −17,358 | 0 | ||
| 2019-03-04 | Ekman Lars Director | Option exercise · Stock Option (Right to Buy) | −28,287 | 0 | ||
| 2019-03-01 | Ketchum Steven B Chief Scientific Officer | Option exercise | +46,000 | $2.50 | $115K | 400,492 |
| 2019-03-01 | Ketchum Steven B Chief Scientific Officer | Sale | −3,503 | $20.94 | $73K | 396,989 |
| 2019-03-01 | Ketchum Steven B Chief Scientific Officer | Sale | −35,398 | $22.10 | $782K | 361,591 |
| 2019-03-01 | Ketchum Steven B Chief Scientific Officer | Sale | −7,099 | $22.64 | $161K | 354,492 |
| 2019-03-01 | Ketchum Steven B Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −46,000 | 194,000 | ||
| 2019-03-01 | Kalb Michael Wayne SVP and CFO | Option exercise | +50,000 | $2.19 | $110K | 70,551 |
| 2019-03-01 | Kalb Michael Wayne SVP and CFO | Option exercise | +19,000 | $2.95 | $56K | 89,551 |
Page 68 of 95 · 1,885 trades